Why So Many Commercial Launches Miss the Mark—And How Technology Can Change That

Despite groundbreaking science and significant investment, more than half of biotech launches underperform against expectations. The causes are rarely scientific. Instead, they’re operational: poor cross-functional alignment, unclear go-to-market strategies, and a lack of scalable infrastructure.

At Project Outlier, we work with emerging biotechs launching their first commercial product, navigating the complex shift from clinical to commercial. The challenges they face are well articulated in the recent Life Science Leader article, “Why So Many Biotech Launches Miss Expectations, And How To Fix It.” The article’s insights mirror what we’ve seen time and again—and where we believe the right technology strategy can make a difference.

Here’s how we think about solving the biotech launch problem:

1. Start Commercial Readiness Early—Not 18 Months Before Launch

All too often, we see commercialization treated as an end-of-phase function. Planning begins 12–18 months before PDUFA, with fragmented efforts to stand up critical functions—market access, field deployment, analytics, systems—under intense time pressure. It’s a recipe for shortfalls.

Instead, commercial readiness should be integrated across the clinical development lifecycle. This includes mapping out technology systems that will scale with the organization, establishing enterprise data models, and implementing tools that enable early HCP and KOL engagement strategies.

We advise biotechs to treat commercial planning as a parallel track, not a milestone.

2. Use Technology to Align Functions—Not Create More Silos

The article rightly highlights a hidden but critical launch risk: misalignment across functions. Commercial, medical affairs, access, marketing, regulatory, and IT often operate in their own swim lanes, leading to conflicting messaging, disconnected timelines, and redundant effort.

Technology can help—but only if it’s implemented strategically. That means:
Using collaborative work management platforms to ensure visibility and accountability

Integrating data from Medical Affairs, MSLs, and Commercial into shared CRMs

Aligning content workflows across Veeva Vault, Salesforce, and omnichannel platforms

At Project Outlier, we ensure that every technology solution is designed to drive clarity, consistency, and cross-functional execution.

3. Let Data Drive Precision in Launch Execution

Successful launches today depend on real-time intelligence and agile execution. Traditional spray-and-pray field tactics are not only expensive—they’re ineffective.

We help clients deploy data platforms and AI-powered insights to:
Prioritize HCP targets based on referral behavior and digital engagement
Optimize channel mix through ongoing A/B testing and CRM analytics
Refine payer strategy with predictive models on access and utilization trends
Biotechs don’t need massive sales forces—they need smarter ones. When powered by data, precision outweighs scale.

4. Build a Scalable, Compliant Infrastructure That Won’t Break on Day 1

Finally, the operational backbone must be ready to handle the demands of launch. That includes validated GxP systems, quality documentation, ERP, CRM, PV systems, patient services platforms, and more.

Many companies attempt to patch systems together in the final stretch—only to realize too late that:
Systems don’t talk to each other
Field teams can’t access the right content

Quality, regulatory, and medical are operating off outdated information

At Project Outlier, we build launch infrastructure that’s fit for purpose and built to scale—balancing compliance, usability, and cost-effectiveness.

Conclusion: The Future of Launch Is Integrated

Biotech companies are under intense pressure to deliver results—and investors are watching. Missing launch expectations doesn’t just hurt near-term revenue; it undermines trust, market credibility, and the momentum needed for future indications.

Technology won’t fix everything—but without it, the risks multiply. Biotechs must treat systems, data, and process alignment as central to their launch strategy—not secondary.

At Project Outlier, we partner with emerging life sciences organizations to build the connective tissue needed for commercial success. If your organization is planning a launch—or struggling to recover from one that underperformed—we’d love to help.